Home > Insider Trading > Filing (0001209191-11-007953)

Filing Details

Accession Number:: 0001209191-11-007953
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-02-08 20:33:46
Reporting Period:: 2011-02-04

Filing Date:: 2011-02-08
Accepted Time:: 2011-02-08 20:33:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235007	Endocyte Inc	ECYT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1139814	Sanderling V Biomedical Co Investment Fund Lp	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1160649	Sanderling V Biomedical Lp	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1169312	Sanderling V Beteiligungs Gmbh & Co Kg	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1267960	Partnership Ltd V Sanderling	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1306695	Sanderling Venture Partners Vi Co Investment Fund Lp	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1316917	Sanderling Venture Partners V, Lp	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1316918	Sanderling Venture Partners V Co Investment Fund, Lp	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1429282	Partnership Limited Vi Sanderling	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1429283	Sanderling Vi Beteiligungs Gmbh & Co Kg	400 S. El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-02-04	785,417	$6.00	785,417	No	4	P	Indirect	By Sanderling V Strategic Exit Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Sanderling V Strategic Exit Fund, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	136,473	Indirect	By Sanderling Venture Partners V, L.P.
Common Stock	33,429	Indirect	By Sanderling V Biomedical, L.P.
Common Stock	13,524	Indirect	By Sanderling V Limited Partnership
Common Stock	12,034	Indirect	By Sanderling V Beteiligungs GmbH & Co. KG

Footnotes

72,502 shares held by Sanderling Venture Partners V, L.P. are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.
Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG and Sanderling VI Limited Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG and Sanderling VI Limited Partnership.
Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
17,759 shares held by Sanderling V Biomedical, L.P. are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.
7,185 shares held by Sanderling V Limited Partnership are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.
6,393 shares held by Sanderling V Beteiligungs GmbH & Co. KG are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.